Treatment Resistant Depression (Pilot)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Treatment resistant depression (TRD) is a major public health problem. Current therapeutic options for this patient population remain limited. With all available treatments, only a sub-set of those patients who achieve an antidepressant response are likely to achieve treatment-induced remission. The need for antidepressant medication that can provide both rapid and long lasting relief of TRD symptoms is widely recognized. There is new evidence that drugs that block NMDA glutamate receptors (NMDA antagonists) are promising candidates for meeting this need. Existing studies in TRD have used only a low-dose, brief infusion of ketamine that would not be expected to re-sensitize the NMDA receptor; in agreement with this theory, these prior studies have found only temporary improvements of depression. Our key hypothesis is that a higher-dose, longer-term ketamine infusion, such as that used in chronic pain studies, would provide a more robust and lasting improvement from depression.
Accordingly, we will be test whether a 100-hour ketamine infusion would be more effective than the standard 40-minute ketamine infusion currently used in other TRD studies. We will randomize subjects to one of 2 arms: (1) 100-hour (+/- 4 hours) ketamine infusion plus clonidine for the entire infusion (2) 40-minute ketamine infusion (plus clonidine) following a 99+/- hour saline infusion. All subjects will receive clonidine, an alpha-2 agonist, to minimize side effects of ketamine (namely, brief/mild psychotic and cognitive symptoms).
| Condition | Intervention |
|---|---|
|
Treatment Refractory Depression |
Drug: Ketamine Drug: Clonidine Drug: placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Safe Ketamine-Based Therapy for Treatment Resistant Depression |
- reduction in HRSD (depression rating) scores by >50% [ Time Frame: approximately 5 years ] [ Designated as safety issue: Yes ]
Primary Aim 1: To evaluate the efficacy and tolerability of a single safener for the prevention of ketamine-induced psychotomimetic effects in healthy humans.
Primary Aim 2: To evaluate the effect of a standardized IV ketamine plus optimal safener combination treatment on change in the severity of depression in patients with TRD.
| Estimated Enrollment: | 20 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: ketamine 100-hour infusion
Participants will receive a 100-hour infusion of ketamine plus a safener (clonidine)
|
Drug: Ketamine
Controlled IV ketamine infusion (0.00225mg/kg-min. [18% (0.0125 mg/kg-min.)
Drug: Clonidine
Participants will receive an approximately 2-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
Other Name: Catapares
|
|
Experimental: ketamine 40-minute infusion
40-minute ketamine infusion following a 99 hours +/- placebo (saline) infusion. Participants will also receive a safener (clonidine)
|
Drug: Ketamine
Controlled IV ketamine infusion (0.00225mg/kg-min. [18% (0.0125 mg/kg-min.)
Drug: Clonidine
Participants will receive an approximately 2-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
Other Name: Catapares
Drug: placebo
IV saline (i.e. placebo ketamine)
|
Detailed Description:
This experiment is a pilot study involving up to 20 healthy males or females between the ages of 21-65 to test whether a 100-hour ketamine infusion plus clonidine would be more effective, with longer lasting results, then the standard 40-minute ketamine infusion (plus clonidine). Each of the 2 arms, will be evaluated using a between subject, double-blind, randomized design,:
- a. Controlled 100-hour IV ketamine infusion b. clonidine safener PO prior to infusion
- a. Controlled 40-minute IV ketamine infusion b. clonidine safener PO prior to infusion c. 99-hour(+/-)IV placebo (saline) infusion
In both conditions, participants will be admitted to the Washington University School of Medicine Clinical Research Unit at Barnes-Jewish Hospital for approximately 124-hours (Monday morning-Saturday morning). Pulse, blood pressure, pulse-oximetry, and an electrocardiogram strip will be routinely monitored. Serial labs and clinical/safety ratings will be done pre-, during, and post-infusion, with the last assessments being used to assure that subjects have returned to their "baseline" prior to discharge from the research unit. Participants will continue to see their primary psychiatrist throughout the study and the PI will request follow-up office reports from the treating psychiatrist for the remaining 44 weeks of the year post study completion.
Eligibility| Ages Eligible for Study: | 21 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- males and females aged 21-65 years;
- DSM-IV diagnosis of Major Depressive Disorder, recurrent, severe;
- depression must be considered treatment refractory as defined by MADRS score of 22 or above which is consistent with other studies;
- on a stable, unchanged dose of permitted antidepressant medication for at least 30 days pre-infusion;
- not currently psychotic and no history of psychosis within the previous 12 months; psychosis reported in the distant past may not be exclusionary if brief, per PI's judgment;
- no history of significant clinical or intolerable side effects or complications from clonidine;
- if a female of child-bearing potential: not pregnant or breast feeding and agrees to use birth control during the time of pre-dosing and infusions; and
- able to give informed consent.
Exclusion Criteria:
- bipolar disorder, schizophrenia, or schizoaffective disorder;
- current or recent substance abuse/dependence (or any lifetime recreational ketamine or PCP use);
- any severe Axis II personality disorder or schizophrenia spectrum disorder that, in the PI's judgment, could confound diagnosis or adherence to treatment;
- the presence of any abnormal laboratory findings or serious medical disorder or condition that may, in the judgment of the PI, confound the assessment of relevant biologic measures or diagnoses including: clinically significant organ system dysfunction; significant and uncontrolled endocrine disease, including diabetes mellitus; hypothyroidism; cardiovascular disease; coagulopathy; significant anemia; significant acute infection; glaucoma; dehydration; epilepsy; any diagnosed cardiac condition causing documented hemodynamic compromise or dysfunction of the SA or AV node; any diagnosed respiratory condition causing documented or clinically recognized hypoxia (e.g., chronic obstructive or restrictive pulmonary disease); after evaluation, anyone determined to have a potentially compromised airway that could be difficult to intubate; fever; BMI less than 14.5 or greater than 30 or approximate at PI discretion; or any medical condition known to interfere with cognitive performance; medication-related exclusions include memantine, or any medication that could be considered contraindicated ketamine;
- current treatment with any medication contraindicated with ketamine or clonidine;
- lifetime illegal use of PCP or ketamine; no clinical use of ketamine for past 3 months
- meets DSM-IV criteria for Mental Retardation;
- currently hospitalized;
- acutely suicidal or homicidal (i.e., in imminent danger with plan, urges and intent to harm oneself or others) including any prior serious attempts (e.g., those requiring hospitalization) at the PI's discretion;
- is pregnant or breast-feeding; unwilling to use birth control if female of child bearing potential
- unable to provide informed consent.
Contacts and Locations| Contact: Julie Schweiger, CCRC | 314-362-3153 | schweigj@psychiatry.wustl.edu |
| Contact: Karen Flavin, RN | 314-362-5242 | flavink@psychiatry.wustl.edu |
| United States, Florida | |
| University of Miami | Active, not recruiting |
| Miami, Florida, United States, 33136 | |
| United States, Missouri | |
| Washington University School of Medicine | Recruiting |
| St. Louis, Missouri, United States, 63110 | |
| Contact: Julie Schweiger, CCRC 314-362-3153 schweigj@psychiatry.wustl.edu | |
| Contact: Karen Flavin, RN 314-362-5242 flavink@psychiatry.wustl.edu | |
| Principal Investigator: Eric Lenze, MD | |
| Sub-Investigator: Nuri B Farber, MD | |
| Principal Investigator: | Eric Lenze, MD | Washington University School of Medicine |
| Principal Investigator: | John W Newcomer, MD | University of Miami |
| Principal Investigator: | Nuri B Farber, MD | Washington University School of Medicine |
More Information
No publications provided
| Responsible Party: | Washington University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT01179009 History of Changes |
| Other Study ID Numbers: | 10-0000 |
| Study First Received: | August 2, 2010 |
| Last Updated: | November 27, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Washington University School of Medicine:
|
depression |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders Ketamine Clonidine Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents |
Therapeutic Uses Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics Sensory System Agents Peripheral Nervous System Agents Antihypertensive Agents Cardiovascular Agents Sympatholytics Autonomic Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists |
ClinicalTrials.gov processed this record on May 22, 2013